about
Guidelines for the use and interpretation of assays for monitoring autophagyAbciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factorThrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasisRecombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generationFunctional characterization of TLR4 +3725 G/C polymorphism and association with protection against overweightCost-effectiveness of a hypertension management programme in an elderly population: a Markov model.Autophagy, Warburg, and Warburg reverse effects in human cancer.Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea?Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study.Supporting the use of a coagulometric method for rivaroxaban control: a hypothesis-generating study to define the safety cut-offsThe emerging role of autophagy in the pathophysiology of diabetes mellitus.NETosis before and after Hyperglycemic Control in Type 2 Diabetes Mellitus Patients.Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome.Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.Waist Circumference Percentiles in Indigenous Argentinean School Children Living at High AltitudesAssociation of the C-344T aldosterone synthase gene variant with essential hypertension: a meta-analysis.Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACsEndocrine therapies and QTc prolongation.Telomere length in the two extremes of abnormal fetal growth and the programming effect of maternal arterial hypertension.Nonresponders to clopidogrel: pharmacokinetics and interactions involved.Pharmacological treatment of obesity in children and adolescents: current status and perspectives.Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease.Chemotherapy and autophagy-mediated cell death in pancreatic cancer cells.New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy.Association between waist circumference and magnesium and uric acid in indigenous Argentinean children living at high altitude.Zymophagy, a novel selective autophagy pathway mediated by VMP1-USP9x-p62, prevents pancreatic cell death.Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells.The prevalence of rheumatoid arthritis in Argentina: a capture-recapture study in a city of Buenos Aires province.Glycaemic changes in patients with chronic kidney disease.Maternal misperceptions of children's overweight in an indigenous Argentinean community.Healthier Lipid Profiles with Vitamin D Supplementation in a Pilot Study in Argentinean Children of Two Ethnicities.Hospitalization and re-hospitalization of people with and without diabetes in La Plata, Argentina: comparison of their clinical characteristics and costs.A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients.Status of Dyslipidemia in Vitamin D Supplemented Argentinean Indigenous Children Versus A Non-supplemented Mixed Population Group.Drug-Induced QTc Interval Prolongation: A Multicenter Study to Detect Drugs and Clinical Factors Involved in Every Day Practice.Inverse association between yerba mate consumption and idiopathic Parkinson's disease. A case-control study.Serotonin and serotonin transporter gene variant in rotating shift workers.Editorial on hypothesis and objectives in clinical trials: superiority, equivalence and non-inferiority.
P50
Q21996341-9E446A14-EA34-484D-BE24-832896A09790Q28183647-7F4B49C8-7F40-4729-8262-510C66FE8E5BQ28196701-03DD9205-DE6B-4001-9294-4A2AF25D88B1Q28200448-AF703229-74F6-48F7-809F-D62BBFEFC11DQ28484281-E5949EBA-10FA-40F2-BF18-406D43E5C64EQ30499940-F520C72F-BD68-4136-8291-63E9FAE2483EQ34092128-27EBB4B1-98F6-4BC1-810B-45FA319D6425Q35688164-D4E51810-F3DF-465E-8816-13275A7D857BQ35707491-E5B08E63-05C8-4008-9E47-F2AF7760B7F2Q35923721-EDF5CBBB-5A1F-4B8C-A6D8-87A089C09D57Q35985421-F8B3F934-7CCB-43DB-80C0-16B3693C72FBQ36231486-7139677F-D89E-4F31-B8FE-11D08AA52069Q36371882-C7152116-D19F-4699-BDDD-934E310FB39AQ36543063-73AF0459-42DE-4E97-8661-20E407629DC4Q36580105-E9FCE953-12BC-41F1-8AB5-0B211F6F9B23Q36672578-BC01E692-137E-4136-AD22-D72A15C0A792Q37681956-73B45BBD-D73F-42A7-9FB7-A511DA4B8DBDQ37704455-8DC23E1C-FDC9-49E9-AF02-1A02535D9017Q37736337-D4277F1B-3B61-4640-B62C-498152C74B1EQ37786622-4EDF8DAC-012D-4490-A115-C299037257DEQ37801370-43D87549-791E-490B-8D9E-BE756BA638B7Q37831317-1BE2E1DA-ACC4-42ED-B6B5-DBFFA9FD9C69Q37831318-5087EF8C-E161-44C9-9FF7-068DA93F77F5Q37878909-D646E3F9-D2B1-4BD4-9E2D-477EF4765705Q38001171-B17CFB67-AB1F-4A59-A783-B5445BFA1889Q38179023-36501158-C31F-4216-93AF-BDC4DD3FDB13Q38800471-2FA20A1B-E95F-4781-A57E-8EEEFD80C4EAQ39617768-BA23F339-C961-434C-A803-596EF4642A41Q39725937-17B0E7B5-8615-4203-A051-97F5FE960754Q39951793-A8D24CE2-11A1-4477-93E1-772512218BEBQ39999925-78C718D5-41F8-4744-8184-6212A2E9E346Q40261628-30BA0C3B-A3F4-4DF0-886E-653154951409Q40497614-8CA0C78F-1068-4C5E-B760-218DE40EBCC1Q40508035-7687036E-D438-46AD-8579-892BD22B59B5Q40747515-37FEEE60-F353-4481-B4C8-A83F9C9BD509Q41063043-8CDA7DD9-F529-4BF0-9DC4-F802CD9B8DE4Q41149661-8E82A878-9BD7-4C91-BFAF-03CC195B335FQ41608644-E4F36B2E-1B5A-4B49-83A9-C1FB084637A4Q42370308-9B17F690-CD74-40B4-876D-BB6B1D1EC171Q42682685-5E885FA1-3C3C-4BD2-A40A-56810BDB8429
P50
description
researcher
@en
հետազոտող
@hy
name
C Gonzalez
@ast
C Gonzalez
@en
C Gonzalez
@es
C Gonzalez
@nl
type
label
C Gonzalez
@ast
C Gonzalez
@en
C Gonzalez
@es
C Gonzalez
@nl
prefLabel
C Gonzalez
@ast
C Gonzalez
@en
C Gonzalez
@es
C Gonzalez
@nl
P106
P1153
7403372616
P31
P496
0000-0002-3772-8850